| Autor: |
Muhammad Yasin Naz, Hareem Fatima, Shazia Shukrullah, Hira Aslam, Sami Ullah, Mohammed Ali Assiri |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Current Pharmaceutical Design. 28:2965-2983 |
| ISSN: |
1381-6128 |
| DOI: |
10.2174/1381612828666220422085702 |
| Popis: |
Abstract: Cancer nano-therapeutics are rapidly evolving and are often used to overcome a number of concerns with traditional drug delivery methods, including non-specific drug targeting and distribution, low oral bioavailability, and poor hydrophilicity. Modern nano-based targeting techniques have been developed as a result of advances in nano vehicle engineering and materials science, which may bring people with cancer a new hope. Clinical trials have been authorized for a number of medicinal nanocarriers. Nanocarriers with the best feasible size and surface attributes have been developed to optimize biodistribution and increase blood circulation duration. Nanotherapeutics can carry preloaded active medicine towards cancerous cells by preferentially leveraging the specific physiopathology of malignancies. In contrast to passive targeting, active targeting strategies involving antigens or ligands, developed against specific tumor sites, boost the selectivity of these curative nanovehicles. Another barrier that nanoparticles may resolve or lessen is drug resistance. Multifunctional and complex nanoparticles are currently being explored and are predicted to usher in a new era of nanoparticles that will allow for more individualized and customized cancer therapy. The potential prospects and opportunities of stimuli-triggered nanosystems in therapeutic trials are also explored in this review. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
